Perez, AntonioCarrasco-Sánchez, Francisco JavierGonzález, CarlosSeguí-Ripoll, José MiguelTrescolí, CarlosEna, JavierBorrell, MireiaGomez Huelgas, Ricardo2023-02-092023-02-092020http://hdl.handle.net/10668/16256This study assessed the efficacy and safety of insulin glargine 300 U/mL (Gla-300) during hospitalization and therapy intensification at discharge in insufficiently controlled people with type 2 diabetes. COBALTA (for its acronym in Spanish, COntrol Basal durante la hospitalizacion y al ALTA) was a multicenter, open-label, single-arm, phase IV trial including 112 evaluable inpatients with type 2 diabetes insufficiently controlled (glycosylated hemoglobin (HbA1c) 8%-10%) with basal insulin and/or non-insulin antidiabetic drugs. Patients were treated with a basal-bolus-correction insulin regimen with Gla-300 during the hospitalization and with Gla-300 and/or non-insulin antidiabetics for 6 months after discharge. The primary endpoint was the HbA1c change from baseline to month 6 postdischarge. HbA1c levels decreased from 8.8%±0.6% at baseline to 7.2%±1.1% at month 6 postdischarge (p Inpatient and intensification therapy at discharge with Gla-300 improved significantly glycemic control of patients with type 2 diabetes insufficiently controlled with other basal insulin and/or non-insulin antidiabetic medication, with high treatment satisfaction. Gla-300 could therefore be a treatment choice for hospital and postdischarge diabetes management.enAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/blood Glucosediabetes mellitushypoglycemiainsulin glarginetype 2AftercareBlood GlucoseDiabetes Mellitus, Type 2HospitalizationHumansInsulin GlarginePatient Dischargeresearch article32928792open access10.1136/bmjdrc-2020-0015182052-4897PMC7488802https://drc.bmj.com/content/bmjdrc/8/1/e001518.full.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488802/pdf